At the beginning of the COVID-19 pandemic, people around the world were comparing the new disease with the flu, also known as influenza. However, while both diseases cause respiratory symptoms, it soon became very clear that there are some important differences between them, as well as between the
Almost two years have passed since the beginning of the COVID-19 pandemic that reshaped the world as we knew it. The virus responsible for the disease not only infected millions of people around the world, but also changed the way people live, work and spend their free time. Despite important
The ongoing COVID-19 pandemic has sparked an unprecedented crisis for governments, healthcare providers, and industries across the world. Biopharmaceutical companies were especially affected, as they were left struggling to develop solutions that will ultimately help diagnose and treat those
The Delta variant of the coronavirus has become the dominant strain around the world, bringing with it an increase in deaths in the US and many other countries. While the victims are almost exclusively unvaccinated, the new surge seems to indicate that the COVID-19 pandemic is far from over. The
In 1982, the U.S. approved human insulin—the first ever recombinant biopharmaceutical drug. Since then, biopharma development has proceeded at an exponential pace, with new innovations redefining, over and over again, the possibilities of medicine. Going forward, biopharma will demand more ef
Biopharmaceuticals are among the most complex and elegant realizations of modern science. But this complexity also comes at great cost. More exactly, biotech-manufacturing facilities need between $200 and $500 million to be built and this process could last up to five years. The Challenges of
